# Resource for Molecular Imaging Agents in Precision Medicine

> **NIH NIH P41** · JOHNS HOPKINS UNIVERSITY · 2020 · $1,203,600

## Abstract

OVERALL RESOURCE: Summary
The Resource for Molecular Imaging Agents in Precision Medicine is a program spanning three campuses of the
Johns Hopkins University (JHU). In our view precision medicine is using all data at hand regarding a particular
patient to enable the best possible care for that patient. We believe that carefully designed molecular imaging
agents can contribute to this. We are now poised to offer a unique Biomedical Technology Resource Center
(BTRC) with a heavy emphasis on the provision of chemistry – new reagents, methods and training in their
development and practice – for molecular imaging. The biological theme of the BTRC is relationships between
cancer, inflammation and immunity, deeper study of which is an unmet need. Although brilliant research
continues worldwide in the development of new molecular imaging agents, few have had actual impact on
addressing human infirmity and many do not justify the cost of their development. In March 2014 the NIBIB
conducted a study “to better understand the reasons why more molecular imaging agents and instrumentation
developed with NIH grant support are not being translated to the clinic nor subsequently commercialized.” To
address those shortcomings, the JHU BTRC will be highly translational by leveraging the Center for Translational
Molecular Imaging (CTMI) at the Johns Hopkins Bayview medical campus, the F. M. Kirby Center for Functional
Brain Imaging at the Kennedy Krieger Institute, the Division of Cancer Imaging Research, and the Division of
Nuclear Medicine and Molecular Imaging, all of which are highly integrated into numerous departments and
schools at JHU. We have generated agents that have been licensed and are in the process of commercialization.
However to date those activities have been performed on an ad hoc basis, and we intend to expand upon them
in two new ways: (1) provide targeted and unique technical research and development (TR&D) projects that will
(2) enable widespread dissemination and training in their use, enhancing the capacity of the centers and divisions
noted above to perform their intended functions – discovery with intent to educate, promote new collaborative,
transdisciplinary research and to manage a variety of conditions, while addressing unanticipated effects of
emerging cancer immunotherapies. The unique aspect of the BTRC is its focus on provision of new, precision
materials, to test these pre-clinically and progress them to human use, delivered on-site or to our collaborators
in a format suitable for their implementation. We will assure proper off-site utilization through continual, reciprocal
education and “push-pull” interactions. The program is agnostic to imaging modality and composition of the
materials to provide, relying upon the specific expertise within each TR&D. In addition to sharing the goal of
leveraging chemistry for imaging, the four TR&Ds will be linked through the aforementioned biological theme.
They can briefly be summarized as ...

## Key facts

- **NIH application ID:** 9984352
- **Project number:** 5P41EB024495-04
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** MARTIN G POMPER
- **Activity code:** P41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,203,600
- **Award type:** 5
- **Project period:** 2017-09-15 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9984352

## Citation

> US National Institutes of Health, RePORTER application 9984352, Resource for Molecular Imaging Agents in Precision Medicine (5P41EB024495-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9984352. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*